Seeking Alpha

Takeda ends development of late-stage diabetes drug

  • "The company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam do not outweigh the potential risks,” Takeda (TKPHF) says, ending development of its late-stage GPR40 agonist TAK-875.
  • The drug was tied to liver damage.
  • The company had hoped the treatment would help offset revenue lost to generic Actos, the diabetes drug which at one time accounted for more than a quarter of Takeda's top-line.
  • Shares fell 5%+ in Tokyo on the news.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)